Global stock

NASDAQUSD

Crinetics Pharmaceuticals

CRNX

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

35/ 100

Overall score·CRNX

Current price

84.95USD

02/09/2026

P/E, P/B

Valuation

Weak

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Akcie se obchoduje za vysoké P/S a P/B, P/E není k dispozici, což naznačuje podhodnocení či nejistotu ohledně ziskovosti. Trzni riziko je spojeno s klinickou exekucí a regulacemi; 7/10 governance rizika a silná hodnota ve vývoji léků ukazuje na potenciál, ale volatilita zůstává vysoká.

§ Outlook vs S&P 500Next 12 months

Probably not

Estimated chance of beating the index: about 41%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Financial results

Financial results·CRNX

M USD

RevenueEBITDANet incomeEBITDA margin

Margins and profitability·CRNX

Net marginEBITDA marginDashed = estimate

Net margin

-6,046.2 %

FY 2025 · reported

EBITDA margin

-6,664.2 %

FY 2026 · estimate

Net margin

0.0 %

last 12 months

Operating margin

-5.3 %

last 12 months

ROE

-42.4 %

last 12 months

FY = fiscal year · TTM = trailing 12 months

Articles about Crinetics Pharmaceuticals, in Czech (1)

Vertex plánuje akvizici Crinetics Pharmaceuticals za 85 USD na akcii v hotovosti

Vertex oznámil záměr koupit společnost Crinetics Pharmaceuticals za 85 USD za akcii v hotovosti, čímž se snaží rozšířit své portfólio v oblasti léčiv. Tato akvizice má hodnotu přibližně 1,5 miliardy dolarů a má být dokončena během několika měsíců.

22 July 2026· 3 min

§ Frequently asked questions

What is Crinetics Pharmaceuticals (CRNX)?

Crinetics Pharmaceuticals (CRNX) is a global stock traded on NASDAQ. Sector: Biotechnology. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Crinetics Pharmaceuticals price today?

As of 2 September 2026, Crinetics Pharmaceuticals trades at about 84.95 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Crinetics Pharmaceuticals?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Crinetics Pharmaceuticals pay a dividend?

Crinetics Pharmaceuticals either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Crinetics Pharmaceuticals a good investment in 2026?

Our AI signal currently rates Crinetics Pharmaceuticals as slightly positive (score 62/100). Financial health comes out at 35/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

§ How to buy Crinetics Pharmaceuticals

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly positive

Contrast

The news is upbeat (signal 62/100), but financial health is weaker (30/100). Consider your own analysis.

News summary

No newer news

Signal 29/09, 21:01

Crinetics vykazuje stabilní krátkodobý růst a vektor sentimentu se zlepšuje, i když cena reaguje opatrně; technické signály podporují mírně pozitivní výhled.

RSI nad 50 a neutrální až pozitivní trend sugerují jemný růst v krátkodobém horizontu. 7–30d změny jsou vesměs kladné, což podtrhuje optimistický krátkodobý výhled.

Risks: Nízká likvidita u menší biotechnologie může vést k vyšší volatile; výsledky klinických studií mohou rychle změnit sentiment; obecná nejistota kolem schválení léků.

More about the signal

RSI nad 50 a neutrální až pozitivní trend sugerují jemný růst v krátkodobém horizontu. 7–30d změny jsou vesměs kladné, což podtrhuje optimistický krátkodobý výhled.

Risks: Nízká likvidita u menší biotechnologie může vést k vyšší volatile; výsledky klinických studií mohou rychle změnit sentiment; obecná nejistota kolem schválení léků.

Signal history· 1

23/0918:0157 · Slightly positive
Konkurenční prostředí a jednotlivé zprávy o společnosti Crinetics vyvažují očekávání; trh vnímá neutrálně s různorodými signály z vývoje léčiv.

The full 90-day signal history is part of Premium.

Ask the AI

DCF valuation

A DCF model is not suitable for this asset class.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 15 of 18

Valuation score

0/ 6

2/6 tests available

1. Below DCF fair value

The complete DCF range or the current price is missing.

2. Well below DCF value

The complete DCF range or the current price is missing.

3. Price vs. the last year

100% above the 1-year low (32.61 USD to 84.95 USD), based on stored daily prices.

4. P/E vs. similar companies

No sector sample with P/E is available.

5. P/E relative to growth

PEG or a reliable growth input is not available.

6. Analyst price target

0.6% vs. the current price, 10 analysts.

Price and fair value

no complete range

The DCF check appears once both the price and the model range are available.

Price vs analyst target

Current price

84.95 USD

Low 85.00 USDHigh 90.00 USD

Current priceAverage: 85.50 USD

DCF gap

no complete range

The DCF check appears once both the price and the model range are available.

Analyst target

+0.6%

Average target 85.50 USD vs. price 84.95 USD.

Analyst consensus

Target range

85.00 USD - 90.00 USD

Coverage

10 analysts

Analyst consensus

2.9 / 5

Changes 180 d

+0 / -8

EPS next year

2.0%

Revenue next year

134.8%

Valuation multiples

-20.9

7.5

213.1

-14.4

52-week range100% above the low

32.61 USD84.95 USD

2,336.0%

0.0%

-42.4%

Price vs 50D23.4%

Price vs 200D72.8%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 02/09/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

good

Management score reflektuje zkušenosti vedení a kapitálovou alokaci, jejichž dopad na budoucí výkon je nejistý vzhledem k vysoce rizikové biotechnologické fázi.

good

Moat zahrnuje možné síťové a regulační výhody v biotechnologickém sektoru, ale současná závislost na klinických výsledcích omezuje trvalé konkurenční výhody.

Information

Type: Global stock
Symbol: CRNX
Exchange: NASDAQ
Currency: USD
Sector: Biotechnology
: 450.0M USD
: 4.0 %
: 0.09

§ Risk profile

Vysoká nejistota ohledně úspěchu klinických studií a regulačních schválení, stejně jako závislost na financování a konkurenci, představují klíčová rizika pro investory do CRNX.

Ask the AI about Crinetics Pharmaceuticals All signals